A groundbreaking study from Washington University reveals that new Alzheimer’s medications could extend patient independence by up to 13 months. Discover how these findings reshape treatment decisions.
Study shows that new Alzheimer's drugs lecanemab and donanemab can significantly extend the period of independent living for patients with early-stage Alzheimer's disease, highlighting potential benefits and risks.
